Korys Merieux

Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors

The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.

By Alaric DeArment

Payers

At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program

At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.

Unlocking Transparency in PBM Pricing

The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.